NutriBand Inc.

Listed Company

NTRBCIK 0001676047NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthOrthopedic, Prosthetic & Surgical Appliances & SuppliesNevadaFY ends Jan 31

Period

FY 2026

Revenue

$2.04M

Net Income

$-8.23M

Total Assets

$7.55M

Equity

$6.68M

Shares Out

Op. Cash Flow

$-5.13M

Business

Nutriband Inc. develops transdermal pharmaceutical products centered on its proprietary AVERSA™ abuse-deterrent transdermal technology designed to reduce abuse, diversion, misuse and accidental exposure of drugs. Its main offerings include AVERSA transdermal patches (lead candidate AVERSA Fentanyl and pipeline products AVERSA Buprenorphine and AVERSA Methylphenidate), transdermal delivery systems for drugs typically given by injection, plus contract manufacturing and contract research and development services. The company reports and manages operations through two subsidiaries, Pocono Pharmaceuticals (manufacturing/Active Intelligence) and 4P Therapeutics (R&D/clinical services). Nutriband primarily operates and derives revenues in the United States and leverages CDMO partnerships and contract manufacturers for development and supply.

Summary from filing dated 2025-04-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-01-31	FY 2025 2025-01-31	FY 2024 2024-01-31	FY 2023 2023-01-31	FY 2022 2022-01-31
Revenue	2	2	2	2	1
Cost of revenues	1	1	1	1	917,844
Research and development	2	3	2	982,227	411,383
Goodwill and intangibles impairment	—	4	—	—	—
Selling, general and administrative	7	4	4	4	4
Total Costs and Expenses	10	12	7	7	8
Loss from operations	−8	−10	−5	−4	−6
Other income	110,864	191,669	16,850	—	—
Loss on extinguishment of debt	—	−368,036	−554,423	—	53,028
Interest expense	−22,535	−21,407	−75,815	—	—
Total other income (expense)	88,329	−197,774	−613,388	—	—
Loss before provision for income taxes	−8	−10	−5	−4	−6
Provision for income taxes	—	—	—	—	—
Net loss	−8	−10	−5	−4	−6
Preferred shares dividend	−22	—	—	—	—
Net loss available to common stockholders - basic	−30	−10	—	−4	−6
Net loss available to common stockholders - diluted	−30	−10	—	—	−6
Net loss per share attributable to common stockholders- basic (in Dollars per share)	−2.58	−0.99	−0.69	−0.53	−0.8
Net loss per share attributable to common stockholders- diluted (in Dollars per share)	−2.58	−0.99	−0.69	−0.53	−0.8
Weighted average common shares outstanding - basic (in Shares)	12	11	8	8	8
Weighted average common shares outstanding - diluted (in Shares)	12	11	8	8	8

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2026 2026-01-31	FY 2025 2025-01-31	FY 2024 2024-01-31	FY 2023 2023-01-31	FY 2022 2022-01-31
Cash and cash equivalents	5	4	492,942	2	5
Accounts receivable-net	118,404	73,847	148,649	113,045	71,380
Inventory- net	117,987	212,041	168,605	229,335	131,648
Prepaid expenses	177,470	196,658	211,667	365,925	370,472
Total Current Assets	5	5	1	3	5
PROPERTY & EQUIPMENT-net	567,255	695,063	774,924	897,735	979,297
Goodwill	2	2	5	5	5
Operating lease right of use asset	72,000	—	31,374	62,754	19,043
Intangible assets-net	200,427	261,092	—	—	—
TOTAL ASSETS	8	7	8	9	13
Accounts payable and accrued expenses	502,654	698,821	680,132	534,679	639,539
Deferred revenue	120,303	155,880	157,502	—	—
Operating lease liability-current portion	32,453	—	34,276	31,291	19,331
Notes payable-current portion	128,871	128,144	127,183	19,740	14,119
Total Current Liabilities	784,281	982,845	999,093	748,613	779,256
Note payable-net of current portion	35,861	58,205	79,826	100,497	101,119
Operating lease liability-net of current portion	48,305	—	—	34,277	—
Total Liabilities	868,447	1	1	883,387	880,375
Commitments and Contingencies	—	—	—	—	—
Preferred stock, $.001 par value, 10,000,000 shares authorized, -3,008,643 and -0- issued and outstanding as of January 31, 2026 and 2025, respectively	3,009	—	—	—	—
Common stock, $.001 par value, 291,666,666 shares authorized, 12,174,883 and 11,107,210 shares issued at January 31, 2026 and 31, 2025, respectively, 12,155,983 and 11,074,810 shares outstanding as of January 31, 2026 and 2025, respectively	12,156	11,075	8,860	7,833	9,155
Additional paid-in-capital	53	45	34	31	30
Accumulated other comprehensive loss	−304	−304	−304	−304	−304
Treasury stock, 18,900 and 32,400 shares at cost, as of January 31, 2026 and 2025,respectively	−86,852	−148,547	−32,641	−32,641	−104,467
Accumulated deficit	−47	−38	−28	−22	−18
Total Stockholders Equity	7	6	6	9	12
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	8	7	8	9	13

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2026 2026-01-31	FY 2025 2025-01-31	FY 2024 2024-01-31	FY 2023 2023-01-31	FY 2022 2022-01-31
Depreciation and amortization	193,797	285,054	287,722	—	—
Operating lease expense	36,000	31,374	31,380	38,813	—
Stock-based compensation-shares issued for services	104,400	133,350	—	113,155	466,900
Stock-based compensation-options and warrants	3	1	499,856	732,130	365,000
Accounts receivable	−44,557	74,802	−153,969	−41,665	42,967
Prepaid expenses	19,188	15,009	154,258	4,547	−370,472
Inventories	94,054	−43,436	60,730	−97,687	−78,800
Deferred revenue	−35,577	−1,622	—	—	—
Operating lease liability	−27,242	−34,276	−31,292	−36,287	−9,234
Accounts payable and accrued expenses	120,943	23,611	198,893	−104,860	−145,259
Net Cash Used In Operating Activities	−5	−5	−4	−3	−3
Purchase of equipment	−5,324	−92,043	−51,761	−79,304	−81,595
Net Cash Used in Investing Activities	−5,324	−92,043	−51,761	−79,304	−81,595
Proceeds from note payable-related party	—	300,000	2	—	—
Proceeds from the exercise of employee stock options	119,206	—	—	—	—
Proceeds from sale of common stock and exercise of warrants	5	8	—	—	583,000
Payment on note payable	−21,617	−20,660	−19,756	−17,795	−5,496
Net Cash Provided by Financing Activities	5	9	2	160,074	8
Net change in cash	263,138	4	−1	−3	5
Interest	1,250	5,631	7,352	4,266	18,598
Income taxes	—	—	—	—	—
Cashless conversion of warrants	82	60	—	1,400	—
Measurement of operating lease right-of-use assets and liabilities	108,000	—	—	—	—
Debt settlement issued by the issuance of common stock and warrants	—	672,956	—	—	—
Preferred Shares issued as Common stock dividend	22	—	—	—	—
Options exercised in exchange for debt	317,110	—	3	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro